BioLife Solutions Inc BLFS
At closeOct 5, 2026, 4:00 PM EDT
After hours · Oct 5, 4:00 PM ET
- YTD
- 0.00%
- 1 year
- 0.00%
- Market cap
- 1.89B
- Revenue (ttm)
- 106.69M
- Profit margin
- 54.35%
- EPS (ttm)
- 0.99
- Shares out
- 48.92M
- P/E ratio
- 39.00
- Forward P/E
- 117.00
- YTD return
- 0.00%
- 1-year return
- 0.00%
- Avg volume
- 1.16M
- Previous close
- 38.61
- Day's range
- 36.96 – 38.83
- 52-week range
- 17.86 – 39.76
- Beta
- 1.82
- Analysts
- Hold
- Price target
- 31.00 (-19.7%)
- Earnings date
- Nov 5, 2026
2Y 0.00 (0.00%)
Key statistics
- Enterprise value
- 1.82B
- PEG ratio
- 15.09
- Price / sales
- 17.71
- Price / book
- 4.49
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 21.50%
- Free cash flow
- 4.66M
- Total cash
- 82.42M
- Total debt
- 15.74M
- Return on equity
- 12.83%
- Short % of float
- 10.82%
- 50-day average
- 36.08
- 200-day average
- 26.77
Analyst view
Consensus: hold
- Strong buy0
- Buy0
- Hold6
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate 0.07.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | 0.05 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | 0.03125 | 0.91 | +0.88 | +2,812.00% |
| May 7, 2026 | Mar 31, 2026 | 0.01 | 0.04 | +0.03 | +300.00% |
| Feb 26, 2026 | Dec 31, 2025 | -0.02 | 0.04 | +0.06 | +300.00% |
| Nov 6, 2025 | Sep 30, 2025 | 0.002 | 0.04 | +0.04 | +1,900.00% |
| Aug 7, 2025 | Jun 30, 2025 | -0.02 | -0.33 | -0.31 | -1,550.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 10, 2026 | Benchmark | down | Buy | Hold |
| Jul 27, 2026 | Stephens & Co. | down | Overweight | Equal-Weight |
| Jul 23, 2026 | Jefferies | down | Buy | Hold |
| Jul 23, 2026 | TD Cowen | down | Buy | Hold |
| Jul 22, 2026 | Lake Street | down | Buy | Hold |
| Jul 22, 2026 | HC Wainwright & Co. | down | Buy | Neutral |
About BioLife Solutions Inc
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- United States
- Website
- biolifesolutions.com
News
BioLife Solutions Inc (BLFS) Shares Surge 3.5% -- What GF Score of 67 Tells Investors 
Apogee Enterprises Posts Upbeat Q2 Earnings, Joins Constellation Energy, Freshworks And Other Big Stocks Moving Higher On Tuesday 
Freshworks Set to Join S&P SmallCap 600; Will Replace BioLife Solutions On October 8 
BioLife Solutions Shareholders Approve Repligen Merger Agreement 
BioLife Solutions, Inc. (NASDAQ:BLFS) Stock Has Consensus Target Price of $31.38 According to Brokerages 
Are BLFS, FTHM, AUUD, VRME Obtaining Fair Deals for their Shareholders? 
Are BLFS, FTHM, AUUD, VRME Obtaining Fair Deals for their Shareholders? 
BioLife Solutions Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioLife Solutions, Inc. - BLFS 
Bank of New York Mellon Corp Purchases New Shares in BioLife Solutions, Inc. $BLFS 
Qiagen (NYSE:QGEN) & BioLife Solutions (NASDAQ:BLFS) Critical Contrast
Your note
Sign in to keep a note on BLFS — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AEBERSOLD SARAH | Officer | Sale | Mar 2, 2026 | 93,360 |
| BERARD TODD C.J. | Officer | Sale | Mar 2, 2026 | 165,940 |
| CASDIN PARTNERS MASTER FUND, L.P. | Beneficial Owner of more than 10% of a Class of Security | Sale | Oct 14, 2025 | 0 |
| DE GREEF RODERICK | Chief Executive Officer | Stock Award(Grant) | Feb 23, 2026 | 744,847 |
| ELLINGSON RACHEL H. | Director | Stock Award(Grant) | Feb 23, 2026 | 57,995 |
| FOSTER KAREN A | Officer | Sale | Mar 22, 2026 | 108,758 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 13.80% | 6,751,135 | 260.66M | Jun 29, 2026 |
| Blackrock Inc. | 13.03% | 6,375,545 | 246.16M | Jun 29, 2026 |
| Casdin Capital, LLC | 9.51% | 4,655,000 | 179.73M | Jun 29, 2026 |
| Invesco Ltd. | 4.58% | 2,240,423 | 86.50M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.01% | 1,964,084 | 75.83M | Jun 29, 2026 |
| State Street Corporation | 3.38% | 1,655,927 | 63.94M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. Rowe Price Small-Cap Stock Fund, Inc. | 5.17% | 2,527,325 | 97.58M | Jun 29, 2026 |
| iShares Trust-iShares Core S&P Small-Cap ETF | 4.93% | 2,410,574 | 93.07M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.99% | 1,461,212 | 56.42M | Jun 29, 2026 |
| T. Rowe Price Eqy. Fd.s, Inc.-T. Rowe Price Inst. Small-Cap Stock Fd. | 2.82% | 1,378,718 | 53.23M | Jun 29, 2026 |
| TR PRICE-Price (T.Rowe) U.S. Small-Cap Core Equity Trust | 2.43% | 1,188,596 | 45.89M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.21% | 1,079,081 | 41.66M | Aug 30, 2026 |